Pharmacological treatment of diabetic retinopathy

1. Porta M, Bandello F. Diabetic retinopathy-a clinical update. Diabetologia 2002; 45: 1617-1634.

2. Gale EAM, Anderson JV. Diabetes mellitus and other disorders of metabolism. In: Kumar P, Clark M (eds). Clinical Medicine. 5th ed. Philadelphia: WB Saunders Elsevier Science: 1069-1123.

3. Nordwall M, Bojestig M, Redquist HJ et al. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Linkoping Diabetes Complications Study. Diabetologia 2004; 47: 1266-1272.

4. Bojestig M, Arnquist HJ, Karlberg BE et al. Unchanged incidence of severe retinopathy in a population of Type 1 diabetic patients with marked reduction of nephropathy. Diabet Med 2000; 15: 863-869.

5. Fong DS, Aiello LP, Ferris FL 3rd et al. Diabetic retinopathy. Diabetes Care 2004; 27: 2540-2553.

6. Rabensteiner D, Abrahamian H, Irsigler K et al. ACE gene polymorphism and proliferative retinopathy in type 1 diabetes: results of a case-control study. Diabetes Care 1999; 22: 1530-1535.

7. Bui BV, Armitage JA, Tolcos M et al. ACE inhibition salvages the visual loss caused by diabetes. Diabetologia 2003; 46: 401-408.

8. Moravski ChJ, Kelly DJ, Cooper ME et al. Retinal Neovascularization Is Prevented by Blockade of the Renin-Aldosteron System. Hypertension 2000; 36: 1099.

9. Chatuverdi N, Sjoelie AK et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinoperil in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 35: 28-31.

10. Boehm BO, Schillind S et al. Elevated serum levels of Nω-carboxymethyl-lysine, an advanced glycation and product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004; 47: 1376-1379.

11. Stratton IM et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000; 321: 405-412.

12. Williams R et al. The evidence Base for Diabetes Care Wiley 2002

13. Klein R, Klein BEK, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Opht 1989; 107: 244-249.

14. Henricsson M, Nilsson A, Janzon L et al. The effect of glyacemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 123-131.

15. Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabet Med 2002; 10: 285-291.

16. Arun CS, Pandit R, Taylor R. Long-term progression of retinopathy after initiation of insulin therapy in Type 2 diabetes: an observational study. Diabetologia 2004; 47: 1380-1384.

17. White MH, Cleary PA, Dahms W et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139: 804-812.

18. DCCT The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983.

19. Berlowitz DR, Ash AS, Hickey EC et al. Hypertension Management in Patients With Diabetes. The need for more aggressive therapy. Diabetes Care 2003; 26: 355-359.

20. Wong TY, Klein R, Klein BE et al. Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol. 2001; 46: 59-80.

21. Klein R, Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801-1815.

22. Zander E, Heinke P, Herfurth S et al. Relations between diabetic retinopathy and cardiovascular neuropathy: a cross-sectional study in IDDM and NIDDM patients. Exp Clin Endocrinol Diabetes 1997; 105: 319-326.

23. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres: The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985; 28 (Suppl): 615-640.

24. Agardh CD, Agardh E, Torffvit O The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Res Clin Pract 1997; 35: 113-121.

25. Marshall G, Garg SK, Jackson WE et al. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993; 100: 1133-1139.

26. Lopes de Faria JM, Jalkh AE, Trempe CL et al. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 1999; 77: 170-175.

27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.

28. Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61: 1086-1097.

29. Marshall G, Garg SK, Jackson WE et al. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993; 100: 1133-1139.

30. Lopes de Faria JM, Jalkh AE, Trempe CL et al. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 1999; 77: 170-175.

31. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.

32. Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.

33. Matthews DR, Stratton IM, Aldington SJ et al. UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004; 122: 1631-1640.

34. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.

35. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.

36. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.

37. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 708-713.

38. Estacio RO, Jeffers BW, Gifford N et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2): B54-B64.

39. Anderson S Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl 1997; 63: S107-S110.

40. Yamagishi S, Amano S, Inagaki Y et al. Angiotensin II-type 1receptor interaction upregulates vascular endothelial growth factormessenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp Clin Res 2003; 29: 75-80.

41. Lyons TJ, Jenkins AJ, Zheng D et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918.

42. Miljanovic B, Glynn RJ, Nathan DM et al. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004; 53: 2883-2892.

43. Davis MD, Fisher MR, Gangnon RE et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report. Invest Ophthalmol Vis Sci 1998; 39: 233-252.

44. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148: 36-69.

45. Duncan LJP, Cullen JF, Ireland JT et al. A three-year trial of atromid therapy in exsudative diabetic retinopathy. Diabetes 1968; 17: 458-467.

46. Houtsmuller AJ Treatment of exsudative diabetic retinopathy with atromid-S. Ophtalmologica 1968; 156: 2-5.

47. Cullen JF, Town SM, Campbell CJ Double-blind trial of atromid-S in exsudative diabetic retinopathy. Transactions of the UK Ophtalmology Society 1974; 94: 554-562.

48. Fried LF, Forrest KYZ et al. Lipid modulation in insulin dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001; 15: 113-119.

49. The Fenofibrate Intervention and Event Lowering in Diabetes - Keech A et al. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.

50. Dunacan IJP et al. A three years trial of atromid therapy in diabetic exsudative neuropaty. Diabetes 1968; 17: 458-467.

51. Guymer RH et al. HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration? Surv Ophthalmol 2005; 50: 194-206.

52. Banerjee S et al. Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? Eye 2004; 18: 821-825.

53. Douglas K et al. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124.

54. Fong MD, Aiello L, Gardner TW et al. the American Diabetes Association. Retinopathy in Diabetes. Diabetes Care 2007; 27: S84-S87.

55. Williams R et al. The evidence Base for Diabetes Care Wiley 2002.

56. Dorin G Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP): can the laser heal the retina without harming it? Semin Ophthalmol. 2004; 19: 62-68.

57. Bandello F, Brancato R, Menchini U et al. Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy. Semin Ophthalmol 2001; 16: 12-18.

58. Donnelly R, Idris I, Forrester JV Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004; 88: 145-151.

59. Danis RP, Bingaman DP, Jirousek M et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171-179.

60. Aiello LP, Bursell SE, Clermont A et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-1480.

61. Donnelly R, Idris I, Forrester JV. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004; 88: 145-151.

62. Campochiaro PA. C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004; 45: 922-931.

63. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu Rev Med 2005; 56: 555-583.

64. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293: 1509-1513.

65. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143-152.

66. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.

67. Nauck M, Karakiulakis G, Perruchoud AP et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341: 309-315.

68. Nauck M, Roth M, Tamm M et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997; 16: 398-406.

69. Antonetti DA, Wolpert EB, DeMaio L et al. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002; 80: 667-677.

70. Martidis A, Duker JS, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-927.

71. Jonas JB, Kreissig I, Sofker A et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57-61.

72. Sorensen TL, Haamann P, Villumsen J et al. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Acta Ophthalmol Scand 2005; 83: 67-70.

73. Pearson P, Levy B Fluconolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. Program and abstracts of the Association for Research in Vision and Ophthalmology 2005 Annual Meeting; May 1-5, 2005; Fort Lauderdale, Florida (Abstract 4673).

74. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2004; 15: 508-518.

75. American Diabetes Association: Retinopathy in diabetes (Position Statement).Diabetes Care 2007; 30 (Suppl 1): S21-S22.

76. Kahn CR. Atlas of Diabetes. London: Science Press 2000.

77. Adler A et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419.